Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20581392 | 0.99 | AR (0.62) | ARHRH3RXFP1SMN1; SMN2THRB | |
| SCHEMBL20581240 | 0.90 | AR (0.51) | ARRXFP1SMN1; SMN2THRBTP53 | |
| SCHEMBL20581396 | 0.89 | AR (0.52) | ARRXFP1SMN1; SMN2THRBTP53 | |
| SCHEMBL20580629 | 0.87 | AR (0.49) | ARTHRBAURKACDK1AURKB | |
| SCHEMBL20581159 | 0.87 | TP53 (0.50) | ARHRH3THRBTP53LMNA | |
| SCHEMBL18975699 | 0.85 | HRAS (0.56) | ARHRH3RXFP1THRBAURKA | |
| SCHEMBL18976141 | 0.83 | AR (0.51) | ARHRH3RXFP1THRBAURKA | |
| SCHEMBL18975731 | 0.82 | AR (0.52) | ARHRH3RXFP1THRBAURKA | |
| SCHEMBL20580684 | 0.81 | ALDH1A1 (0.47) | ARRXFP1SMN1; SMN2THRBTP53 | |
| SCHEMBL20580855 | 0.81 | RAB9A (0.50) | ARSMN1; SMN2LMNANPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640507-B2 | PBD antibacterial agents | KING'S COLLEGE LONDON (GB) | 2020-05-05 | — | — | US | disclosed |
| US-20180354958-A1 | PBD ANTIBACTERIAL AGENTS | Secretary of State for Health and Social Care (GB) | 2018-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640507-B2 | PBD antibacterial agents | OPRD1, XDH, SBDS | AR 3276/4885HRH3 28/4885RXFP1 209/4885 |
| US-20180354958-A1 | PBD ANTIBACTERIAL AGENTS | OPRD1, XDH, SBDS | AR 3276/4885HRH3 28/4885RXFP1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.